Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Cash from Financing Activities (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Cash from Financing Activities for 3 consecutive years, with $39000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 197.5% to $39000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $327000.0 through Dec 2025, down 99.29% year-over-year, with the annual reading at $327000.0 for FY2025, 99.29% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $39000.0 at Mereo BioPharma, up from -$134000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $46.8 million in Q2 2024, with the low at -$594000.0 in Q3 2024.
  • Average Cash from Financing Activities over 3 years is $7.8 million, with a median of $39000.0 recorded in 2025.
  • The sharpest move saw Cash from Financing Activities tumbled 107.51% in 2024, then surged 197.5% in 2025.
  • Over 3 years, Cash from Financing Activities stood at $7.9 million in 2023, then tumbled by 100.51% to -$40000.0 in 2024, then soared by 197.5% to $39000.0 in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $39000.0, -$134000.0, and $422000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.